Skip to main content

Table 1 Baseline characteristics of all patients versus non-HSCT eligible patients only in the LYM-3002 trial

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Variable All patients (n = 487) Clinically ineligible for HSCT only (n = 407)
Age at baseline 64.29 65.82
Female 26.1 % 26.8 %
European Union 27.9 % 31.2 %
North America 2.9 % 6.3 %
Rest of the World 69.2 % 65.6 %
Stage II 6 % 6 %
Stage III 20 % 22 %
Stage IV 74 % 72 %
ECOG 0 40 % 43 %
ECOG 1 47 % 47 %
ECOG 2 13 % 10 %
Mean patient weight (kg) 70.59 70.03
Body surface area (m2) 1.80 1.79
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, HSCT haematopoietic stem cell transplantation